

# The British Antibiotic and Silver Impregnated Catheters for ventriculoperitoneal Shunts multi-centre randomised control trial

<b>Submission date</b> 11/12/2012	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 17/12/2012	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 06/02/2023	<b>Condition category</b> Nervous System Diseases	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims:

Two new devices have been introduced to try to reduce shunt infection; Bactiseal and Silverline shunts. This study will compare these new shunts to standard shunts. Our goal is to establish which provides most protection against infection and to ensure standardisation of care.

### Who can participate?

Children and adults with newly diagnosed hydrocephalus.

### What does the study involve?

Patients will be randomly chosen to receive either standard, Bactiseal or Silverline shunts. The patient will have a follow up every three months via the telephone and a questionnaire by post.

### What are the possible benefits and risks of participating?

There will be no immediate direct benefit to those taking part. But there should be benefits to future patients requiring this treatment as they will potentially have reduced shunt infection. The main risk of infection is complications for the patients which can lead to prolonged hospital stay, multiple operations and reduced IQ.

### Where is the study run from?

Alder Hey Childrens Hospital NHS Foundation Trust.

### When is study starting and how long is it expected to run for?

Recruitment will start in early 2013, for 2 years. Patients will be followed up for a maximum of 2.5 years.

### Who is funding the study?

National Institute of Health Research Health Technology Assessment Programme

Who is the main contact?

Mr Tom Kearns

thomas.kearns@liv.ac.uk

## Contact information

### Type(s)

Scientific

### Contact name

Mr Conor Mallucci

### Contact details

Alder Hey Childrens NHS Foundation Trust

Eaton Road

Liverpool

United Kingdom

L12 2AP

## Additional identifiers

### Protocol serial number

Version 2.0; HTA 10/104/30

## Study information

### Scientific Title

National three-arm, double blind multi-centre randomised controlled trial comparing Bactiseal (antibiotic-impregnated), Silverline (silver-impregnated) and standard (non-impregnated) VPS in patients with newly diagnosed hydrocephalus undergoing insertion of their first permanent shunt

### Acronym

BASICS

### Study objectives

Shunt failure due to infection has plagued this neurosurgical advance ever since it was developed. The incidence of shunt infection varies markedly in the literature from 3-27% (2-6) and is higher in certain groups, e.g. neonates and children under 1 year old, patients treated with a previous temporary external ventricular drain (EVD). Episodes of shunt infection have a significant impact on patients and the NHS and require prolonged inpatient hospitalisation, additional surgery to remove the infected hardware, placement of a temporary EVD, intravenous and intrathecal antibiotics, and further surgery to place a new shunt once the infection has been treated. Other clinical consequences of infection including epilepsy, reduced IQ and loculation have often been reported but never formally studied in the context of a prospective clinical trial. This trial thus addresses the primary question of which shunt catheter is most effective in reducing shunt infection and also has secondary questions addressing the consequences of infection in a clinical and financial context.

More details can be found here: <http://www.hta.ac.uk/project/2902.asp>

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Not provided at time of registration

### **Study design**

Three-arm multi-centre phase III randomised controlled trial

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Newly diagnosed hydrocephalus

### **Interventions**

We will randomly allocate patients to a standard non impregnated ventriculoperitoneal shunt (VPS), a

Silverline (Silver impregnated) VPS or a Bactiseal (antibiotic impregnated) VPS on a ratio of 1:1:

1. All VPS

used for the trial are CE marked medical devices being used for their intended purpose.

### **Intervention Type**

Device

### **Phase**

Phase III

### **Primary outcome(s)**

Early infection (within 6 months) following insertion of the first de novo VPS

### **Key secondary outcome(s)**

1. The proportion of delayed VPS infections (occurring > 6 months following de novo insertion)
2. Which organisms and their resistance/sensitivities, subsequently infect these three alternative VPS
3. The clinical impact of each VPS infection
4. The infection rate following the first (non-infected) clean VPS revision for mechanical failure
5. The cost-effectiveness and health economics of antibiotic and silver impregnated VPS compared to standard VPS
6. The diagnostics of suspected shunt infections through molecular diagnostic approaches

### **Completion date**

01/08/2013

## **Eligibility**

**Key inclusion criteria**

1. Newly diagnosed hydrocephalus of any aetiology (including idiopathic intracranial hypertension)
2. VPS is the primary treatment option
3. Clear CSF sample at the time of shunt insertion
  - 3.1. Failed primary endoscopic third ventriculostomy allowed
  - 3.2. Previous indwelling ventricular access device (e.g. Ommaya or Rickham reservoir or similar) allowed
  - 3.3. Previous indwelling EVD allowed

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Total final enrolment**

1605

**Key exclusion criteria**

1. Previous indwelling VPS
2. Active and on-going CSF or peritoneal infection
3. Multi-loculated hydrocephalus requiring multiple VPS or neuro-endoscopy
4. Ventriculo-atrial or ventriculo-pleural shunt planned
5. Allergy to antibiotics associated with the antibiotic shunt

**Date of first enrolment**

01/03/2013

**Date of final enrolment**

01/08/2013

**Locations****Countries of recruitment**

United Kingdom

England

Ireland

**Study participating centre**

**Alder Hey Childrens NHS Foundation Trust**  
Liverpool  
United Kingdom  
L12 2AP

## Sponsor information

### Organisation

Alder Hey Children's Hospital Foundation Trust (UK)

### ROR

<https://ror.org/00p18zw56>

## Funder(s)

### Funder type

Government

### Funder Name

Health Technology Assessment Programme: 10/104/30

### Alternative Name(s)

NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

## Results and Publications

### Individual participant data (IPD) sharing plan

Not provided at time of registration

### IPD sharing plan summary

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

<a href="#">Results article</a>	results	26/10/2019	17/09/2019	Yes	No
<a href="#">Results article</a>	results	01/03/2020	03/04/2020	Yes	No
<a href="#">Results article</a>	Post hoc analysis	01/02/2023	06/02/2023	Yes	No
<a href="#">Protocol article</a>	protocol	03/01/2014		Yes	No
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes